Characterizing Biologics Using Dynamic Imaging Particle Analysis - Overcoming limitations of volumetric techniques and detecting transparent particles. - BioPharm International


Characterizing Biologics Using Dynamic Imaging Particle Analysis
Overcoming limitations of volumetric techniques and detecting transparent particles.

BioPharm International Supplements
Volume 24, Issue 8, pp. s4-s9

However, the system cannot really measure to that small a level because of sampling. The Nyquist–Shannon sampling theorem states that in the conversion of a continuous signal to a discrete signal, one can only resolve the original signal by sampling at two times the rate of the original sample. To use the previous example, one can only resolve a 2.5 m signal by sampling at a minimum rate of 1.25 m. Using the same example, with a 2.5-m minimum pixel size, the smallest object the system can possibly resolve is 5 m in size. In terms of particle analysis, the term "resolve" would apply only to counting a particle, and not to any higher-level description of the particle, such as shape. Indeed, the higher the order of the measurement desired, the more resolution is needed (3).

As a result of diffraction limitations inherent to microscopy-based systems and sampling theory as discussed above, dynamic particle imaging systems are limited to counting particles no smaller than 1 m in size, and being able to differentiate shape information for particles no smaller than 2–3 m in size (4). To image particles smaller than these limits requires electron microscopy, where the sample size and number of particles that can be imaged are extremely limited, and therefore statistically significant numbers of particles cannot be achieved. Other synthetic image techniques, in which an image is produced by sampling another characteristic (e.g., Brownian motion, or atomic force microscopy), can also be used for smaller particles, but these are not direct optical images.

The second factor to consider when using dynamic imaging particle analysis is the effect of thresholding. Not only are digital images quantized in the spatial domain in terms of a limited number of pixels, but each pixel is quantized in terms of gray-scale (or color in the case of color imaging) resolution, also. In most typical systems, the gray-scale (i.e., intensity) value of each pixel is limited to 256 levels or eight bits. In a color system, there are eight bits each of red, green, and blue. To make rapid measurement calculations on the image data in particle image analysis, the gray-scale intensity is reduced to a single bit (i.e., on or off) through a thresholding process. In imaging particle analysis, this thresholding is performed by comparing each pixel of an incoming image that may contain particles with the same pixel of a background image taken when no particles were present in the system. Because most systems are "bright-field" or backlit, a particle in the optical path will reduce the amount of light passing through to the camera sensor, therefore the incoming pixel intensity will be darker (i.e., a smaller number) than the background calibrated value for the same pixel. For this reason, most imaging particle analysis systems will define a threshold as either a delta value or percent value darker than the background.

For opaque particles, thresholding in this fashion (i.e., in which pixels are darker than the background) works quite well. However, as previously mentioned, protein aggregates are semitransparent and amorphous. In fact, because of the way light is bent through the structure of the aggregate, many of the pixels within the aggregate will be brighter than the background. Therefore, if only a dark threshold is used, the result will be that a single aggregate will be chopped up into multiple small particles by the thresholding process. This technique results in a severe overcounting of small particles and undercounting of large particles (5).

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here